ArticleBMC gastroenterology2025
Good performance of monoclonal antibody-based stool H. pylori antigen tests in acute nonvariceal upper gastrointestinal bleeding patients.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- CurrentJGH open : an open access journal of gastroenterology and hepatology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundAcute nonvariceal upper gastrointestinal bleeding (ANVUGIB) is a common clinical emergency disease with high morbidity and mortality. H. pylori (HP) testing during hospitalization increases the eradication rate of HP and improves the prognosis of patients. The use of stool samples to detect HP has potential clinical application value in ANVUGIB patients, but its accuracy has yet to be verified.
aimTo evaluate the accuracy of the monoclonal antibody-based stool antigen test (SAT) and PCR fluorescent probe assay for detecting fecal HP in patients with ANVUGIB.
methodsWe evaluated the accuracy of monoclonal antibody-based SAT and PCR fluorescent probe assays for fecal HP detection in ANVUGIB patients hospitalized at Beijing Luhe Hospital Affiliated with Capital Medical University between April 2022 and December 2023. Fecal HP nucleic acid detection by nested PCR combined with Sanger sequencing was used as the gold standard.
resultsIn total, 82 patients with ANVUGIB were included. All patients received PPI medication, and 35.4% received antibiotic therapy. Compared with serum HP antibody and fluorescent probe PCR, monoclonal antibody-based SAT has relatively good performance in detecting fecal HP (AUC = 0.841, 0.785 and 0.795, respectively). The combination of these two methods for the detection of HP can improve diagnostic sensitivity but does not improve diagnostic accuracy. The fecal hemoglobin content, use of antibiotics, and duration of PPI use had no significant effect on the accuracy of monoclonal antibody-based SAT or fluorescent probe PCR detection of fecal HP.
conclusionMonoclonal antibody-based SAT has good performance for detecting fecal HP in ANVUGIB patients and is not affected by the fecal hemoglobin content, antibiotic use, or PPI use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.